RxDoctor Payments Data

Ashley Kim, PA

Surgical · Seattle, WANPI 1164992574

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Getinge USA Sales, LLC at 44.6% of the total. Reporting peaked in 2024 at $1,235 and has fallen 83.6% since, to $203 in 2025.

$1,988in general payments, 2019–2025

Across 25 payments — averaging $79.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Getinge USA Sales, LLC$886
  • Davol Inc.$225
  • Zimmer Biomet$178
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$157
  • BD$144
  • Medical Device Business Services, Inc.$137
  • plus $261 from 4 others

What the payments were for

  • Travel & lodging$73337%
  • Food & beverage$1,11856%
  • Education$1377%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,988 in reported general payments places this provider in the 85th percentile of 404 surgical providers in Washington.

See all surgical providers in Washington

Medicare billing

Part B allowed, 2024
$2,324
Medicare patients
25
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$8,823
Mupirocin27$223

Paid to pharmacies, not to this prescriber.

Other surgical in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →